DNA methylation and hydroxymethylation in hematologic differentiation and transformation

Current Opinion in Cell Biology

Volumn 37, Issue , 2015, Pages 91-101

  Ko, Myunggon ^a   An, Jungeun ^a   Rao, Anjana ^b,c,d  

^a Ulsan National Institute of Science and Technology   (South Korea)

^b LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d SANFORD CONSORTIUM FOR REGENERATIVE MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYMETHYLCYTOSINE; 5 METHYLCYTOSINE; DIOXYGENASE; TEN ELEVEN TRANSLOCATION PROTEIN; UNCLASSIFIED DRUG; DNA;

CELL DIFFERENTIATION; CELL FATE; CELL RENEWAL; DEMETHYLATION; DNA METHYLATION; DNA MODIFICATION; ENZYME MECHANISM; EPIGENETICS; GENE MUTATION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL; HYDROXYMETHYLATION; LOSS OF FUNCTION MUTATION; MALIGNANT TRANSFORMATION; NONHUMAN; ONCOGENE; OXIDATION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FAMILY; REVIEW; TET1 GENE; TET2 GENE; TET3 GENE; ANIMAL; BLOOD CELL; CELL LINEAGE; CYTOLOGY; GENETIC EPIGENESIS; GENETICS; HUMAN; METABOLISM; OXIDATION REDUCTION REACTION;

ANIMALS; BLOOD CELLS; CELL DIFFERENTIATION; CELL LINEAGE; DNA; DNA METHYLATION; EPIGENESIS, GENETIC; HUMANS; OXIDATION-REDUCTION;

EID: 84947249842     PISSN: 09550674     EISSN: 18790410     Source Type: Journal    
DOI: 10.1016/j.ceb.2015.10.009     Document Type: Review

References (81)

1. Ooi S.K., O'Donnell A.H., Bestor T.H. Mammalian cytosine methylation at a glance. J Cell Sci 2009, 122:2787-2791.
2. Pastor W.A., Aravind L., Rao A. TETonic shift: biological roles of TET proteins in DNA demethylation and transcription. Nat Rev Mol Cell Biol 2013, 14:341-356.
3. Tahiliani M., Koh K.P., Shen Y., Pastor W.A., Bandukwala H., Brudno Y., Agarwal S., Iyer L.M., Liu D.R., Aravind L., et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009, 324:930-935.
4. Ito S., Shen L., Dai Q., Wu S.C., Collins L.B., Swenberg J.A., He C., Zhang Y. Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science 2011, 333:1300-1303.
5. He Y.F., Li B.Z., Li Z., Liu P., Wang Y., Tang Q., Ding J., Jia Y., Chen Z., Li L., et al. Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science 2011, 333:1303-1307.
6. Shen L., Song C.X., He C., Zhang Y. Mechanism and function of oxidative reversal of DNA and RNA methylation. Annu Rev Biochem 2014, 83:585-614.
7. Spruijt C.G., Gnerlich F., Smits A.H., Pfaffeneder T., Jansen P.W., Bauer C., Munzel M., Wagner M., Muller M., Khan F., et al. Dynamic readers for 5-(hydroxy)methylcytosine and its oxidized derivatives. Cell 2013, 152:1146-1159.
8. Bachman M., Uribe-Lewis S., Yang X., Burgess H.E., Iurlaro M., Reik W., Murrell A., Balasubramanian S. 5-Formylcytosine can be a stable DNA modification in mammals. Nat Chem Biol 2015, 11:555-557.
9. Bachman M., Uribe-Lewis S., Yang X., Williams M., Murrell A., Balasubramanian S. 5-Hydroxymethylcytosine is a predominantly stable DNA modification. Nat Chem 2014, 6:1049-1055.
10. Raiber E.A., Murat P., Chirgadze D.Y., Beraldi D., Luisi B.F., Balasubramanian S. 5-Formylcytosine alters the structure of the DNA double helix. Nat Struct Mol Biol 2015, 22:44-49.
11. Ko M., An J., Bandukwala H.S., Chavez L., Aijo T., Pastor W.A., Segal M.F., Li H., Koh K.P., Lahdesmaki H., et al. Modulation of TET2 expression and 5-methylcytosine oxidation by the CXXC domain protein IDAX. Nature 2013, 497:122-126.
12. Zhang Q., Zhao K., Shen Q., Han Y., Gu Y., Li X., Zhao D., Liu Y., Wang C., Zhang X., et al. Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6. Nature 2015, 525:389-393.
13. Huang Y., Rao A. Connections between TET proteins and aberrant DNA modification in cancer. Trends Genet 2014, 30:464-474.
14. Ko M., An J., Pastor W.A., Koralov S.B., Rajewsky K., Rao A. TET proteins and 5-methylcytosine oxidation in hematological cancers. Immunol Rev 2015, 263:6-21.
15. Xu J., Wang Y.Y., Dai Y.J., Zhang W., Zhang W.N., Xiong S.M., Gu Z.H., Wang K.K., Zeng R., Chen Z., et al. DNMT3A Arg882 mutation drives chronic myelomonocytic leukemia through disturbing gene expression/DNA methylation in hematopoietic cells. Proc Natl Acad Sci U S A 2014, 111:2620-2625.
16. Mayle A., Yang L., Rodriguez B., Zhou T., Chang E., Curry C.V., Challen G.A., Li W., Wheeler D., Rebel V.I., et al. Dnmt3a loss predisposes murine hematopoietic stem cells to malignant transformation. Blood 2015, 125:629-638.
17. Celik H., Mallaney C., Kothari A., Ostrander E.L., Eultgen E., Martens A., Miller C.A., Hundal J., Klco J.M., Challen G.A. Enforced differentiation of Dnmt3a-null bone marrow leads to failure with c-Kit mutations driving leukemic transformation. Blood 2015, 125:619-628.
18. Trowbridge J.J., Snow J.W., Kim J., Orkin S.H. DNA methyltransferase 1 is essential for and uniquely regulates hematopoietic stem and progenitor cells. Cell Stem Cell 2009, 5:442-449.
19. Broske A.M., Vockentanz L., Kharazi S., Huska M.R., Mancini E., Scheller M., Kuhl C., Enns A., Prinz M., Jaenisch R., et al. DNA methylation protects hematopoietic stem cell multipotency from myeloerythroid restriction. Nat Genet 2009, 41:1207-1215.
20. Challen G.A., Sun D., Jeong M., Luo M., Jelinek J., Berg J.S., Bock C., Vasanthakumar A., Gu H., Xi Y., et al. Dnmt3a is essential for hematopoietic stem cell differentiation. Nat Genet 2012, 44:23-31.
21. Challen G.A., Sun D., Mayle A., Jeong M., Luo M., Rodriguez B., Mallaney C., Celik H., Yang L., Xia Z., et al. Dnmt3a and Dnmt3b have overlapping and distinct functions in hematopoietic stem cells. Cell Stem Cell 2014, 15:350-364.
22. Tadokoro Y., Ema H., Okano M., Li E., Nakauchi H. De novo DNA methyltransferase is essential for self-renewal, but not for differentiation, in hematopoietic stem cells. J Exp Med 2007, 204:715-722.
23. Huang Y.P.W., Shen Y., Tahiliani M., Liu D.R., Rao A. The behaviour of 5-hydroxymethylcytosine in bisulfite sequencing. PLoS One 2009, 5:e8888.
24. Ji H., Ehrlich L.I., Seita J., Murakami P., Doi A., Lindau P., Lee H., Aryee M.J., Irizarry R.A., Kim K., et al. Comprehensive methylome map of lineage commitment from haematopoietic progenitors. Nature 2010, 467:338-342.
25. Bock C., Beerman I., Lien W.H., Smith Z.D., Gu H., Boyle P., Gnirke A., Fuchs E., Rossi D.J., Meissner A. DNA methylation dynamics during in vivo differentiation of blood and skin stem cells. Mol Cell 2012, 47:633-647.
26. Hu M., Krause D., Greaves M., Sharkis S., Dexter M., Heyworth C., Enver T. Multilineage gene expression precedes commitment in the hemopoietic system. Genes Dev 1997, 11:774-785.
27. Gaudet F., Hodgson J.G., Eden A., Jackson-Grusby L., Dausman J., Gray J.W., Leonhardt H., Jaenisch R. Induction of tumors in mice by genomic hypomethylation. Science 2003, 300:489-492.
28. Yang L., Rau R., Goodell M.A. DNMT3A in haematological malignancies. Nat Rev Cancer 2015, 15:152-165.
29. Ley T.J., Ding L., Walter M.J., McLellan M.D., Lamprecht T., Larson D.E., Kandoth C., Payton J.E., Baty J., Welch J., et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med 2010, 363:2424-2433.
30. Russler-Germain D.A., Spencer D.H., Young M.A., Lamprecht T.L., Miller C.A., Fulton R., Meyer M.R., Erdmann-Gilmore P., Townsend R.R., Wilson R.K., et al. The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers. Cancer Cell 2014, 25:442-454.
31. Jeong M., Sun D., Luo M., Huang Y., Challen G.A., Rodriguez B., Zhang X., Chavez L., Wang H., Hannah R., et al. Large conserved domains of low DNA methylation maintained by Dnmt3a. Nat Genet 2014, 46:17-23.
32. Ono R., Taki T., Taketani T., Taniwaki M., Kobayashi H., Hayashi Y. LCX, leukemia-associated protein with a CXXC domain, is fused to MLL in acute myeloid leukemia with trilineage dysplasia having t(10;11)(q22;q23). Cancer Res 2002, 62:4075-4080.
33. Lorsbach R.B., Moore J., Mathew S., Raimondi S.C., Mukatira S.T., Downing J.R. TET1 a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23). Leukemia 2003, 17:637-641.
34. Huang H., Jiang X., Li Z., Li Y., Song C.X., He C., Sun M., Chen P., Gurbuxani S., Wang J., et al. TET1 plays an essential oncogenic role in MLL-rearranged leukemia. Proc Natl Acad Sci U S A 2013, 110:11994-11999.
35. Cimmino L., Dawlaty M.M., Ndiaye-Lobry D., Yap Y.S., Bakogianni S., Yu Y., Bhattacharyya S., Shaknovich R., Geng H., Lobry C., et al. TET1 is a tumor suppressor of hematopoietic malignancy. Nat Immunol 2015, 16:653-662.
36. Delhommeau F., Dupont S., Della Valle V., James C., Trannoy S., Masse A., Kosmider O., Le Couedic J.P., Robert F., Alberdi A., et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009, 360:2289-2301.
37. Langemeijer S.M., Kuiper R.P., Berends M., Knops R., Aslanyan M.G., Massop M., Stevens-Linders E., van Hoogen P., van Kessel A.G., Raymakers R.A., et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 2009, 41:838-842.
38. Ko M., Huang Y., Jankowska A.M., Pape U.J., Tahiliani M., Bandukwala H.S., An J., Lamperti E.D., Koh K.P., Ganetzky R., et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 2010, 468:839-843.
39. Pronier E., Almire C., Mokrani H., Vasanthakumar A., Simon A., da Costa Reis Monte Mor B., Masse A., Le Couedic J.P., Pendino F., Carbonne B., et al. Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbs erythroid and granulomonocytic differentiation of human hematopoietic progenitors. Blood 2011, 118:2551-2555.
40. Chang Y.I., Damnernsawad A., Allen L.K., Yang D., Ranheim E.A., Young K.H., Zhang J., Kong G., Wang J., Liu Y., et al. Evaluation of allelic strength of human TET2 mutations and cooperation between Tet2 knockdown and oncogenic Nras mutation. Br J Haematol 2014, 166:461-465.
41. Quivoron C., Couronne L., Della Valle V., Lopez C.K., Plo I., Wagner-Ballon O., Do Cruzeiro M., Delhommeau F., Arnulf B., Stern M.H., et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 2011, 20:25-38.
42. Lemonnier F., Couronne L., Parrens M., Jais J.P., Travert M., Lamant L., Tournillac O., Rousset T., Fabiani B., Cairns R.A., et al. Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters. Blood 2012, 120:1466-1469.
43. Odejide O., Weigert O., Lane A.A., Toscano D., Lunning M.A., Kopp N., Kim S., van Bodegom D., Bolla S., Schatz J.H., et al. A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. Blood 2014, 123:1293-1296.
44. Sakata-Yanagimoto M., Enami T., Yoshida K., Shiraishi Y., Ishii R., Miyake Y., Muto H., Tsuyama N., Sato-Otsubo A., Okuno Y., et al. Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat Genet 2014, 46:171-175.
45. Palomero T., Couronne L., Khiabanian H., Kim M.Y., Ambesi-Impiombato A., Perez-Garcia A., Carpenter Z., Abate F., Allegretta M., Haydu J.E., et al. Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nat Genet 2014, 46:166-170.
46. Couronne L., Bastard C., Bernard O.A. TET2 and DNMT3A mutations in human T-cell lymphoma. N Engl J Med 2012, 366:95-96.
47. Figueroa M.E., Abdel-Wahab O., Lu C., Ward P.S., Patel J., Shih A., Li Y., Bhagwat N., Vasanthakumar A., Fernandez H.F., et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010, 18:553-567.
48. Ko M., Bandukwala H.S., An J., Lamperti E.D., Thompson E.C., Hastie R., Tsangaratou A., Rajewsky K., Koralov S.B., Rao A. Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice. Proc Natl Acad Sci U S A 2011, 108:14566-14571.
49. Li Z., Cai X., Cai C.L., Wang J., Zhang W., Petersen B.E., Yang F.C., Xu M. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood 2011, 118:4509-4518.
50. Moran-Crusio K., Reavie L., Shih A., Abdel-Wahab O., Ndiaye-Lobry D., Lobry C., Figueroa M.E., Vasanthakumar A., Patel J., Zhao X., et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 2011, 20:11-24.
51. Muto T., Sashida G., Oshima M., Wendt G.R., Mochizuki-Kashio M., Nagata Y., Sanada M., Miyagi S., Saraya A., Kamio A., et al. Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders. J Exp Med 2013, 210:2627-2639.
52. Shide K., Kameda T., Shimoda H., Yamaji T., Abe H., Kamiunten A., Sekine M., Hidaka T., Katayose K., Kubuki Y., et al. TET2 is essential for survival and hematopoietic stem cell homeostasis. Leukemia 2012, 26:2216-2223.
53. Kunimoto H., Fukuchi Y., Sakurai M., Sadahira K., Ikeda Y., Okamoto S., Nakajima H. Tet2 disruption leads to enhanced self-renewal and altered differentiation of fetal liver hematopoietic stem cells. Sci Rep 2012, 2:273.
54. Kunimoto H., Fukuchi Y., Sakurai M., Takubo K., Okamoto S., Nakajima H. Tet2-mutated myeloid progenitors possess aberrant in vitro self-renewal capacity. Blood 2014, 123:2897-2899.
55. Busque L., Patel J.P., Figueroa M.E., Vasanthakumar A., Provost S., Hamilou Z., Mollica L., Li J., Viale A., Heguy A., et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet 2012, 44:1179-1181.
56. Haferlach T., Nagata Y., Grossmann V., Okuno Y., Bacher U., Nagae G., Schnittger S., Sanada M., Kon A., Alpermann T., et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 2014, 28:241-247.
57. Papaemmanuil E., Gerstung M., Malcovati L., Tauro S., Gundem G., Van Loo P., Yoon C.J., Ellis P., Wedge D.C., Pellagatti A., et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 2013, 122:3616-3627. quiz 3699.
58. Abdel-Wahab O., Gao J., Adli M., Dey A., Trimarchi T., Chung Y.R., Kuscu C., Hricik T., Ndiaye-Lobry D., Lafave L.M., et al. Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo. J Exp Med 2013, 210:2641-2659.
59. Lobry C., Ntziachristos P., Ndiaye-Lobry D., Oh P., Cimmino L., Zhu N., Araldi E., Hu W., Freund J., Abdel-Wahab O., et al. Notch pathway activation targets AML-initiating cell homeostasis and differentiation. J Exp Med 2013, 210:301-319.
60. De Vita S., Schneider R.K., Garcia M., Wood J., Gavillet M., Ebert B.L., Gerbaulet A., Roers A., Levine R.L., Mullally A., et al. Loss of function of TET2 cooperates with constitutively active KIT in murine and human models of mastocytosis. PLoS One 2014, 9:e96209.
61. Soucie E., Hanssens K., Mercher T., Georgin-Lavialle S., Damaj G., Livideanu C., Chandesris M.O., Acin Y., Letard S., de Sepulveda P., et al. In aggressive forms of mastocytosis, TET2 loss cooperates with c-KITD816V to transform mast cells. Blood 2012, 120:4846-4849.
62. Shih A.H., Jiang Y., Meydan C., Shank K., Pandey S., Barreyro L., Antony-Debre I., Viale A., Socci N., Sun Y., et al. Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia. Cancer Cell 2015, 27:502-515.
63. Nakagawa T., Lv L., Nakagawa M., Yu Y., Yu C., D'Alessio A.C., Nakayama K., Fan H.Y., Chen X., Xiong Y. CRL4(VprBP) E3 ligase promotes monoubiquitylation and chromatin binding of TET dioxygenases. Mol Cell 2015, 57:247-260.
64. Song S.J., Ito K., Ala U., Kats L., Webster K., Sun S.M., Jongen-Lavrencic M., Manova-Todorova K., Teruya-Feldstein J., Avigan D.E., et al. The oncogenic microRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformation. Cell Stem Cell 2013, 13:87-101.
65. Song S.J., Poliseno L., Song M.S., Ala U., Webster K., Ng C., Beringer G., Brikbak N.J., Yuan X., Cantley L.C., et al. MicroRNA-antagonism regulates breast cancer stemness and metastasis via TET-family-dependent chromatin remodeling. Cell 2013, 154:311-324.
66. Cheng J., Guo S., Chen S., Mastriano S.J., Liu C., D'Alessio A.C., Hysolli E., Guo Y., Yao H., Megyola C.M., et al. An extensive network of TET2-targeting MicroRNAs regulates malignant hematopoiesis. Cell Rep 2013, 5:471-481.
67. Kim Y.H., Pierscianek D., Mittelbronn M., Vital A., Mariani L., Hasselblatt M., Ohgaki H. TET2 promoter methylation in low-grade diffuse gliomas lacking IDH1/2 mutations. J Clin Pathol 2011, 64:850-852.
68. Dang L., Jin S., Su S.M. IDH mutations in glioma and acute myeloid leukemia. Trends Mol Med 2010, 16:387-397.
69. Xu W., Yang H., Liu Y., Yang Y., Wang P., Kim S.H., Ito S., Yang C., Wang P., Xiao M.T., et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell 2011, 19:17-30.
70. Rampal R., Alkalin A., Madzo J., Vasanthakumar A., Pronier E., Patel J., Li Y., Ahn J., Abdel-Wahab O., Shih A., et al. DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia. Cell Rep 2014, 9:1841-1855.
71. Wang Y., Xiao M., Chen X., Chen L., Xu Y., Lv L., Wang P., Yang H., Ma S., Lin H., et al. WT1 recruits TET2 to regulate its target gene expression and suppress leukemia cell proliferation. Mol Cell 2015, 57:662-673.
72. Loenarz C., Schofield C.J. Expanding chemical biology of 2-oxoglutarate oxygenases. Nat Chem Biol 2008, 4:152-156.
73. Arioka Y., Watanabe A., Saito K., Yamada Y. Activation-induced cytidine deaminase alters the subcellular localization of Tet family proteins. PLoS One 2012, 7:e45031.
74. Zhang Q., Liu X., Gao W., Li P., Hou J., Li J., Wong J. Differential regulation of the ten-eleven translocation (TET) family of dioxygenases by O-linked beta-N-acetylglucosamine transferase (OGT). J Biol Chem 2014, 289:5986-5996.
75. Lu F., Liu Y., Jiang L., Yamaguchi S., Zhang Y. Role of Tet proteins in enhancer activity and telomere elongation. Genes Dev 2014, 28:2103-2119.
76. Huang Y., Chavez L., Chang X., Wang X., Pastor W.A., Kang J., Zepeda-Martinez J.A., Pape U.J., Jacobsen S.E., Peters B., et al. Distinct roles of the methylcytosine oxidases Tet1 and Tet2 in mouse embryonic stem cells. Proc Natl Acad Sci U S A 2014, 111:1361-1366.
77. Hon G.C., Song C.X., Du T., Jin F., Selvaraj S., Lee A.Y., Yen C.A., Ye Z., Mao S.Q., Wang B.A., et al. 5mC oxidation by Tet2 modulates enhancer activity and timing of transcriptome reprogramming during differentiation. Mol Cell 2014, 56:286-297.
78. Bestor T.H., Edwards J.R., Boulard M. Notes on the role of dynamic DNA methylation in mammalian development. Proc Natl Acad Sci U S A 2015, 112:6796-6799.
79. Schubeler D. Function and information content of DNA methylation. Nature 2015, 517:321-326.
80. Wang L., Zhou Y., Xu L., Xiao R., Lu X., Chen L., Chong J., Li H., He C., Fu X.D., et al. Molecular basis for 5-carboxycytosine recognition by RNA polymerase II elongation complex. Nature 2015.
81. Kang J., Lienhard M., Pastor W.A., Chawla A., Novotny M., Tsagaratou A., Lasken R.S., Thompson E.C., Surani M.A., Koralov S.B., et al. Simultaneous deletion of the methylcytosine oxidases Tet1 and Tet3 increases transcriptome variability in early embryogenesis. Proc Natl Acad Sci U S A 2015, 112:E4236-E4245.